about
Advances and Challenges of Liposome Assisted Drug DeliverySingle-walled carbon nanotube interactions with HeLa cellsCore-controlled polymorphism in virus-like particlesAn integrated approach for the rational design of nanovectors for biomedical imaging and therapy.Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicEnabling individualized therapy through nanotechnologyCombination of polymer technology and carbon nanotube array for the development of an effective drug delivery system at cellular level.Multi-stage delivery nano-particle systems for therapeutic applicationsMathematical modeling of cancer progression and response to chemotherapy.A Protocol for the Design of Protein and Peptide Nanostructure Self-Assemblies Exploiting Synthetic Amino Acids.Computational validation of protein nanotubesIntracellular distribution of TiO2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificityAntibiological barrier nanovector technology for cancer applications.Nanovehicular intracellular delivery systems.Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging.Magnetic nanoparticle drug carriers and their study by quadrupole magnetic field-flow fractionation.Magnetically modulated nanosystems: a unique drug-delivery platform.Synergistic effect of reduced polypeptide micelle for co-delivery of doxorubicin and TRAIL against drug-resistance in breast cancer.Polymer-functionalized nanoparticles: from stealth viruses to biocompatible quantum dots.Phototriggerable liposomes: current research and future perspectives.Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects.Prospects of nano-material in breast cancer management.Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model.PEG-PBLG nanoparticle-mediated HSV-TK/GCV gene therapy for oral squamous cell carcinoma.Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect.Flow chamber analysis of size effects in the adhesion of spherical particlesEngineering multi-stage nanovectors for controlled degradation and tunable release kinetics.Development of a liposomal nanodelivery system for nevirapineCardiovascular nanomedicine: a posse ad esse.Mitigated cytotoxicity and tremendously enhanced gene transfection efficiency of PEI through facile one-step carbamate modification.S-layer coated emulsomes as potential nanocarriers.The Diverse Range of Possible Cell Membrane Interactions with Substrates: Drug Delivery, Interfaces and Mobility.Enhancing Tumor Cell Response to Chemotherapy through the Targeted Delivery of Platinum Drugs Mediated by Highly Stable, Multifunctional Carboxymethylcellulose-Coated Magnetic Nanoparticles.
P2860
Q26773160-428097E5-03D7-4851-8B18-F09CFA9172EFQ28382896-01F4BC66-DF2B-49B0-97D2-3C558C594AEBQ33269435-CC8A911E-43E3-4956-85B8-7F10E9A06337Q33679533-E6002DE8-37D6-4D93-847D-D2FC72B5062FQ33830955-4F0ED8B0-F953-413A-9115-204C24A8BF8CQ33911056-96CE623A-6B01-4DA7-BE94-7FEE2DB768BBQ33917755-7247533D-B4BF-4D7E-8402-22EB5AE8B906Q33947878-D3A6361F-7060-4B7E-B0D0-2A038672BD41Q34166491-AF4992AC-0394-4AB7-9274-3EE8C4894FE5Q34577219-011D0CE1-1101-432C-B92E-04A873E7CAC6Q36212512-81610B84-0418-472C-AB6A-D86FC7EEF515Q36507287-44B4DC95-A5E4-4EF4-BEAD-7E84717477CEQ36835036-72D87F5A-E148-4DB4-B965-D8D9039346A5Q36903797-506E0C7D-2AE4-4A45-94E9-0C8CF9D1CBA4Q37058812-C69DB606-62A9-4B3C-8C5A-1EBA51C9C8C8Q37229797-02E7AC1B-6999-4A1D-8E1A-168317F731A4Q37376480-AB140AE0-48C1-4921-9D66-E92990C7CC4AQ37617371-0FBD689F-0963-4861-84D3-A47B4155C37EQ37641692-739931D1-1042-4647-AAF9-2BB675E3447EQ37643742-C3698B8E-C394-4164-ACE4-C7A9BD4C0670Q37689852-AB550E50-9DFA-4E71-AF2C-19B989F0C5A7Q37955034-29248E3B-70A7-45F4-9CDE-DD394A13E4E8Q38084156-29B5A772-DFAD-4B34-A658-17359649EDBCQ39903504-D6BE7FE8-E91D-47D6-82BF-8F86B6C138FAQ40025984-7217641E-75C0-45AD-A4BF-C40EA73034D5Q41023286-5F05ACA6-E881-4257-8525-E4EA3406B690Q41909701-6BE8E6A4-658F-4CE6-A92C-64A079445DDAQ42068139-336D08D9-8701-4578-A0B2-24DC4362425BQ42242819-9860EE1E-A41F-42E6-B841-011EB68BC30DQ43232585-3DBE3EDD-D302-4C9A-A341-811E66CB8CABQ43860458-E0AC4987-6C63-4EEE-A5CD-F3D4DEBED5ADQ46606872-E85C5B7D-AECA-4B5C-B899-8C0E5DD5ADF0Q47302175-B34C4488-646C-4B59-9203-D8BFD4EA3C3BQ53783135-01D868AB-8458-4106-A744-2D24738BEF80
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Nanovector therapeutics.
@ast
Nanovector therapeutics.
@en
type
label
Nanovector therapeutics.
@ast
Nanovector therapeutics.
@en
prefLabel
Nanovector therapeutics.
@ast
Nanovector therapeutics.
@en
P1476
Nanovector therapeutics.
@en
P2093
Mauro Ferrari
P304
P356
10.1016/J.CBPA.2005.06.001
P577
2005-08-01T00:00:00Z